GSK PLC (GS71.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
As of 01:51PM CEST. Market open.
| Previous Close | 20.50 |
| Open | 20.51 |
| Bid | 20.56 x N/A |
| Ask | 20.59 x N/A |
| Day's Range | 20.51 - 20.57 |
| 52 Week Range | 20.51 - 20.94 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireBioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections
Simply Wall St.GSK First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GSK ( LON:GSK ) First Quarter 2024 Results Key Financial Results Revenue: UK£7.36b (up 5.9% from 1Q 2023). Net income...
PA Media: MoneyGSK raises profit guidance as vaccine demand grows
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.
© 2024 Yahoo. All rights reserved.